tesamorelin 2 MG Injection

RxCUI: 1044587
RxNorm name: tesamorelin 2 MG Injection
Display name: tesamorelin 2 MG Injection
Full name: tesamorelin 2 MG Injection
Term type: SCD
Status: DailyMed mapping
Updated: 2026-06-04 23:38:54

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
022505	Egrifta	tesamorelin	351(a)	Disc	2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
EGRIFTA SV	TESAMORELIN	Theratechnologies Inc.	3d783378-b02d-4f19-99dd-0fc91a042224	2026-07-29	Warnings, Adverse reactions	Exact identifier rxcui: 1044587

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
3d783378-b02d-4f19-99dd-0fc91a042224	tesamorelin 2 MG Injection [PSN] · tesamorelin 2 MG Injection [SCD]	2	8	These highlights do not include all the information needed to use EGRIFTA SV safely and effectively. See full prescribing information for EGRIFTA SV. EGRIFTA SV ® (tesamorelin) for injection, for subcutaneous use Initial U.S. Approval: 2010	20251223